

# Bias in control selection associated with the use of rapid tests in influenza vaccine effectiveness studies

*Eero Poukka, Caitriona Murphy, Loretta Mak, Samuel M. S. Cheng, Malik Peiris, Tim K. Tsang, Sheena G. Sullivan, Benjamin J. Cowling*

## Contents

<b>Table S1.</b> Detailed rapid test specification.....	2
<b>Table S2.</b> Characteristics of participants according to rapid test of influenza A. ....	3
<b>Table S3.</b> Characteristics of participants according to rapid test of influenza B.....	4
<b>Table S4.</b> Vaccine effectiveness (VE) against influenza A among participants aged less than 18 years ( $\geq 18$ years) based on PCR or rapid test with 95% confidence interval.....	5
<b>Table S5.</b> Vaccine effectiveness (VE) against influenza A among participants aged 18 years or more (18 years) based on PCR or rapid test with 95% confidence interval.....	6
<b>Figure S1.</b> Study enrolment.....	9
<b>Figure S2.</b> Influenza A and B cases over calendar time.....	9

**Table S1.** Detailed rapid test specification.

Assay	SARS-CoV-2 & Influenza A/B & RSV Antigen Kit (Colloidal Gold)
Manufacturer	Goldsite Diagnostics Inc., Shenzhen, China
Country of Origin	P.R. China
Certification	CE-IVD
Swab Type	Nasal swab
Reported Sensitivity and specificity	SARS-CoV-2: 93.0%; 100% Influenza A: 85.0%; 99.3% Influenza B: 95.0%; 100% RSV: 92.3%; 100%
Format	Cassette
Method	Colloidal Gold
Volume applied into card/cassette	2 drops (~60µL)
Incubation	15 minutes
Readout	Visual: colored band
Limit of detection	SARS-CoV-2: 49 TCID 50/mL Influenza A(H3N2): 4.0 x 10 <sup>4</sup> TCID 50/mL Influenza A(H1N1): 2.0 x 10 <sup>4</sup> TCID 50/mL RSV: 1.6x10 <sup>4</sup> TCID 50/mL
Cross reactivity against other human virus	The results showed no cross reactivity

**Table S2.** Characteristics of participants according to rapid test of influenza A.

	False negative	False positive	True negative	True positive
<b>N</b>	97	5	1,276	313
<b>Sex</b>				
Male	30	2	571	149
Female	67	3	705	164
<b>Age groups</b>				
0–4	5	1	231	54
5–9	9	1	288	54
10–17	13	0	177	46
18–49	47	3	410	108
50+	23	0	170	51
<b>Comorbidities</b>				
Yes	11	0	118	25
No	86	5	1,158	288
<b>Influenza vaccination for season 2023/24</b>				
Yes	22	1	496	77
No	75	4	807	236
<b>Previous season influenza vaccination (2022/23)</b>				
Yes	24	0	421	77
No	73	5	855	236
<b>Number of COVID-19 vaccinations</b>				
0	10	1	252	70
1–2	25	0	354	73
≥3	62	4	670	170
<b>Days since symptom onset</b>				
One days	60	3	681	188
Two days	9	0	201	57
Three days	28	2	394	68

**Table S3.** Characteristics of participants according to rapid test of influenza B.

	False negative	False positive	True negative	True positive
<b>N</b>	36	1	1,512	142
<b>Sex</b>				
Male	22	0	663	67
Female	14	1	849	75
<b>Age groups</b>				
0–4	2	0	274	15
5–9	6	1	326	19
10–17	5	0	195	36
18–49	21	0	482	65
50+	2	0	235	7
<b>Presence of chronic medical conditions</b>				
Yes	3	0	143	8
No	33	1	1,369	134
<b>Influenza vaccination for season 2023/24</b>				
Yes	1	1	544	23
No	35	0	968	119
<b>Previous season influenza vaccination (2022/23)</b>				
Yes	3	1	495	23
No	33	0	1,017	119
<b>Number of COVID-19 vaccinations</b>				
0	4	0	313	16
1–2	12	0	399	41
≥3	20	1	800	85
<b>Days since symptom onset</b>				
One day	17	0	852	63
Two days	6	1	234	26
Three days	13	0	426	53

**Table S4.** Vaccine effectiveness (VE) against influenza A among participants aged less than 18 years by PCR or rapid test with 95% confidence interval.

	<b>VE by PCR (95% CI)</b>	<b>VE by rapid test (95% CI)</b>	<b>Bias-corrected VE by rapid test (95% CI)*</b>	<b>Bias-corrected VE by rapid test (95% CI)†</b>
1. Exclusion of influenza B and SARS-CoV-2 by PCR (N=738) ‡	55% (30–72%)	53% (24–71%)	55% (33–70%)	55% (33–70%)
2. Exclusion of influenza B by PCR and adjusting for COVID-19 vaccination (N=796) ‡	52% (25–70%)	50% (20–69%)	52% (41–62%)	53% (42–62%)
3. Exclusion of influenza B by PCR (N=796)	52% (25–70%)	51% (21–70%)	53% (8–76%)	54% (31–69%)
4. All study participants (N=879)	47% (17–67%)	46% (13–67%)	48% (14–69%)	48% (22–65%)
5. Exclusion of influenza B and SARS-CoV-2 by rapid test (N=755)	53% (27–70%)	50% (21–69%)	53% (30–68%)	53% (30–69%)
6. Exclusion of influenza B by rapid test and adjusting for COVID-19 vaccination (N=808)	50% (48–86%)	48% (17–68%)	50% (39–59%)	51% (40–60%)
7. Exclusion of influenza B by rapid test (N=808)	50% (22–68%)	49% (18–68%)	51% (27–67%)	51% (27–68%)

VE = Vaccine effectiveness

\* Diagnostic accuracy estimates based on data from the study participants (sensitivity = 85.1% and specificity = 99.7%)

† Diagnostic accuracy estimates of manufacturer (sensitivity = 85.0% and specificity = 99.3%)

‡ These estimates should be considered the most valid in this table.

**Table S5.** Vaccine effectiveness (VE) against influenza A among participants aged 18 years or more by PCR or rapid test with 95% confidence interval.

	<b>VE by PCR (95% CI)</b>	<b>VE by rapid test (95% CI)</b>	<b>Bias-corrected VE by rapid test (95% CI)*</b>	<b>Bias-corrected VE by rapid test (95% CI)†</b>
1. Exclusion of influenza B and SARS-CoV-2 by PCR (N=576) ‡	38% (-21–69%)	26% (-53–65%)	31% (-17–69%)	28% (-16–55%)
2. Exclusion of influenza B by PCR and adjusting for COVID-19 vaccination (N=717) ‡	41% (-10–69%)	32% (-35–67%)	37% (5–58%)	35% (12–53%)
3. Exclusion of influenza B by PCR (N=717)	41% (-9–69%)	31% (-38–66%)	36% (-128–82%)	34% (-4–58%)
4. All study participants (N=812)	37% (-19–67%)	26% (-50–65%)	29% (-51–66%)	28% (-12–54%)
5. Exclusion of influenza B and SARS-CoV-2 by rapid test (N=615)	37% (-21–68%)	26% (-52–65%)	31% (-19–60%)	27% (-17–55%)
6. Exclusion of influenza B by rapid test and adjusting for COVID-19 vaccination (N=740)	39% (-14–68%)	30% (-40–66%)	34% (2–56%)	33% (7–51%)
7. Exclusion of influenza B by rapid test (N=740)	39% (-14–68%)	29% (-43–65%)	34% (-11–60%)	31% (-8–56%)

VE = Vaccine effectiveness

\* Diagnostic accuracy estimates based on data from the study participants (sensitivity = 69.4% and specificity = 99.5%)

† Diagnostic accuracy estimates of manufacturer (sensitivity = 85.0% and specificity = 99.3%)

‡ These estimates should be considered the most valid in this table.

**Table S6.** Vaccine effectiveness (VE) against influenza A by PCR or rapid test with 95% confidence interval during H3N2 predominance (December 2023 – February 2024).

	<b>VE by PCR (95% CI)</b>	<b>VE by rapid test (95% CI)</b>	<b>Bias-corrected VE by rapid test (95% CI)*</b>	<b>Bias-corrected VE by rapid test (95% CI)†</b>
1. Exclusion of influenza B and SARS-CoV-2 by PCR (N=751) ‡	59% (31–76%)	54% (20–77%)	58% (35–73%)	57% (35–72%)
2. Exclusion of influenza B by PCR and adjusting for COVID-19 vaccination (N=871) ‡	56% (27–74%)	52% (18–73%)	57% (43–67%)	55% (42–66%)
3. Exclusion of influenza B by PCR (N=871)	58% (29–75%)	53% (19–73%)	57% (18–77%)	56% (34–71%)
4. All study participants (N=920)	56% (27–74%)	52% (17–73%)	55% (19–75%)	54% (31–70%)
5. Exclusion of influenza B and SARS-CoV-2 by rapid test (N=778)	58% (30–76%)	53% (19–74%)	57% (34–72%)	57% (34–72%)
6. Exclusion of influenza B by rapid test and adjusting for COVID-19 vaccination (N=882)	55% (26–74%)	51% (16–72%)	55% (40–66%)	54% (41–64%)
7. Exclusion of influenza B by rapid test (N=882)	57% (13–73%)	52% (18–73%)	56% (33–71%)	55% (33–70%)

VE = Vaccine effectiveness

\* Diagnostic accuracy estimates based on data from the study participants (sensitivity = 76.3% and specificity = 99.6%)

† Diagnostic accuracy estimates of manufacturer (sensitivity = 85.0% and specificity = 99.3%)

‡ These estimates should be considered the most valid in this table.

**Table S7.** Vaccine effectiveness (VE) against influenza A by PCR or rapid test with 95% confidence interval during H1N1 predominance (March – August 2024).

	<b>VE by PCR (95% CI)</b>	<b>VE by rapid test (95% CI)</b>	<b>Bias-corrected VE by rapid test (95% CI)*</b>	<b>Bias-corrected VE by rapid test (95% CI)†</b>
1. Exclusion of influenza B and SARS-CoV-2 by PCR (N=563) ‡	33% (-14–61%)	30% (-25–61%)	33% (-8–59%)	32% (-8–57%)
2. Exclusion of influenza B by PCR and adjusting for COVID-19 vaccination (N=642) ‡	34% (-10–61%)	32% (-21–62%)	35% (11–52%)	33% (12–48%)
3. Exclusion of influenza B by PCR (N=642)	33% (-12–61%)	29% (-25–61%)	33% (-24–64%)	32% (-8–57%)
4. All study participants (N=771)	21% (-34–54%)	17% (-48–54%)	19% (-49–56%)	18% (-26–47%)
5. Exclusion of influenza B and SARS-CoV-2 by rapid test (N=)	29% (-20–58%)	26% (-32–59%)	29% (-15–56%)	27% (-16–54%)
6. Exclusion of influenza B by rapid test and adjusting for COVID-19 vaccination (N=666)	30% (-17–59%)	27% (-29–60%)	30% (5–48%)	29% (9–45%)
7. Exclusion of influenza B by rapid test (N=666)	29% (-20–58%)	25% (-32–58%)	28% (-15–54%)	27% (-13–53%)

VE = Vaccine effectiveness

\* Diagnostic accuracy estimates based on data from the study participants (sensitivity = 76.3% and specificity = 99.6%)

† Diagnostic accuracy estimates of manufacturer (sensitivity = 85.0% and specificity = 99.3%)

‡ These estimates should be considered the most valid in this table.



Figure S1. Study enrolment.




Figure S2. Influenza A and B cases over calendar time

